Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

Free Thinking: From promise to practice: immuno-oncology in action

Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically...

Research Partnership

- PMLiVE

Pfizer to form specialty drugs unit after Allergan takeover

Will merge its consumer portfolio with Allergan's ophthalmology and aesthetics brands

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Soaring sales of Pfizer’s Prevnar lead to calls for price cut

Revenue from the family of pneumonia vaccines rose 43% in the fourth quarter

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Research Partnership

- PMLiVE

Baxalta inks $1.6bn immuno-oncology deal with Symphogen

Comes as the company's takeover negotiations with Shire continue

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

- PMLiVE

Quintiles wins New Models of Care award at PMEA

Rewarded for its rheumatology project for Pfizer

- PMLiVE

Xalkori set for rapid review in new lung cancer indication

Pfizer could produce first FDA-approved biomarker-driven therapy for ROS1-positive NSCLC

- PMLiVE

Pfizer signs $1bn cancer antibody deal with BioAtla

Aims to overcome one of the limitations of antibody-drug conjugate drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links